Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
Wednesday, May 6, 2026 1 min read
Key Takeaway: Vertex Pharmaceuticals has secured a reimbursement agreement in Germany for its gene-edited therapy CASGEVY® (exagamglogene autotemcel). This agreement allows eligible patients aged 12 and older with severe sickle cell disease or transfusion-dependent beta thalassemia to access this innovative one-time treatment. This marks a significant advancement in treatment options available in Germany.
Market Sentiment Analysis
POSITIVE FACTORS
Reimbursement agreement enhances patient access to CASGEVY®.
Innovative treatment offers hope for severe sickle cell disease and beta thalassemia.
First-time availability of such a therapy in Germany.
Full Press Release Details
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-t
Frequently Asked Questions
What is CASGEVY®?
CASGEVY® is a CRISPR/Cas9 gene-edited therapy for severe sickle cell disease and beta thalassemia.
Who is eligible for CASGEVY® treatment in Germany?
Patients aged 12 years and older with severe sickle cell disease or transfusion-dependent beta thalassemia are eligible.
What does the reimbursement agreement entail?
The agreement ensures sustainable access to CASGEVY® for eligible patients in Germany.
Why is this agreement significant?
It marks the first time such a gene therapy is available in Germany for these conditions.